Ongoing research, exemplified by the current phase III clinical trial (NCT03941093) focusing on metastatic pancreatic cancer with results expected in 2024, further highlights the challenges associated with harnessing CTGF as a transformative treatment for highly fibrotic disorders. This evidence concerns the gene CCN2 and pancreatic neoplasm.